熱門資訊> 正文
Centessa Pharmaceuticals prices $250M offering at $21.5 per ADS
2025-11-12 16:22
- Clinical-stage pharmaceutical company Centessa Pharmaceuticals (CNTA) priced an underwritten public offering of ~11.63M ADSs, each representing one ordinary share, at a price to the public of $21.50 per ADS.
- The aggregate gross proceeds are expected to be ~$250M.
- All ADSs sold in the offering were offered by Centessa. The underwriters have a 30-day option to purchase up to an additional ~1.74M ADSs.
- The offering is expected to close on or about November 14, 2025
- The stock price fell 3.5% on Wednesday during pre-market hours of trading.
More on Centessa Pharmaceuticals
- Centessa rated Outperform at Oppenheimer on ORX750 potential
- Seeking Alpha’s Quant Rating on Centessa Pharmaceuticals
- Historical earnings data for Centessa Pharmaceuticals
- Financial information for Centessa Pharmaceuticals
推薦文章
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
